Cannabis and neuroleptic agents in schizophrenia.
A description is given of 10 schizophrenic patients whose condition was acutely aggravated following cannabis use, despite verified adequate depot treatment with neuroleptics. It is concluded that cannabis use constitutes a risk factor for schizophrenic patients, and the hypothesis is suggested that there may exist a cannabis-neuroleptics antagonistic interaction. Recent research in cannabis pharmacokinetics is presented in support of this hypothesis.
D000328:Adult; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D002186:Cannabinoids / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000150:complications*; D012559:Schizophrenia / Q000139:chemically induced* / Q000188:drug therapy; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D002186:Cannabinoids; D003692:Delayed-Action Preparations